N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten. W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.

Size: px
Start display at page:

Download "N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten. W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S."

Transcription

1 N.E. Verstegen A.P.W.M. Maat F.J. Lagerwaard M.A. Paul M.I. Versteegh J.J. Joosten W. Lastdrager E.F. Smit B.J. Slotman J.J.M.E. Nuyttens S.Senan Submitted

2 10 Salvage surgery for local failures after stereotactic ablative radiotherapy for lung malignancies

3 Chapter 10 Abstract Introduction The literature on surgical salvage for potentially resectable recurrences following stereotactic radiotherapy (SABR) is limited. We describe our experience with salvage surgery in 17 patients who developed a local recurrence. Methods Patients who underwent surgical salvage for a local recurrence following SABR for pulmonary malignancies were identified from two Dutch institutional databases. Complications were scored using the Dindo-Clavien-classification. Results Seventeen patients who underwent surgery for a local recurrence were identified. Patients were treated with SABR for either primary non-small cell lung cancers (N=9) or solitary metastasis (N=8). Four patients with solitary metastasis had two surgeries for separate recurrences. Median time to local recurrence was 15.6 months. Recurrences were diagnosed with CT- and/or 18FDG-PET-imaging, with 5 patients also having a pre-surgical pathological diagnosis. Extensive adhesions were observed during 5 resections, requiring conversion from a thoracoscopic procedure to thoracotomy in 3 procedures. Four patients experienced complications post-surgery; grade 2 (N=2) and grade 3a (N=2), respectively. All had viable tumor cells in the resection specimens. Median length of hospital stay was 7 days (range 4-15 days) and 30-day mortality was 0%. Lymph node dissection revealed mediastinal metastases in 3 patients, all of whom received adjuvant therapy. Median follow-up after surgery was 41 months and median overall survival was 38 months. Conclusions Experience with 21 surgical procedures for local recurrences post-sabr revealed only two grade IIIa complications, and a 30-day mortality of 0%. Median overall survival after surgery was 38 months. Our results suggests that salvage surgery can be safely performed after SABR.

4 Surgical salvage for local failures following SABR 151 Introduction While surgery remains the treatment of choice for operable patients with early stage, resectable, non-small cell lung cancer (NSCLC), stereotactic ablative radiotherapy (SABR) is the recommended therapy for unfit patients, and for those who decline surgery 1,2. Although randomized controlled trials comparing surgery and SABR have failed to complete accrual 3, several studies using propensity score matching, matched pair analysis, Markov modeling and meta-analytic methodologies for patients with early stage NSCLC reveal comparable outcomes for both treatment modalities 4,5. Increasingly, fitter and potentially operable patients are being referred for SABR 6,7. Consequently, careful follow-up and early recognition of local recurrences has become increasingly important for such patients. There is limited literature on salvage surgery following SABR for pulmonary malignancies 8-10, reporting on a total of 16 such patients. We report on the feasibility and outcomes in the largest series to date of patients who underwent surgical salvage for local failure after SABR. Materials and methods We retrospectively identified patients who were suspected of having a local recurrence following SABR, and who underwent surgical salvage from institutional databases in both the VU University Medical Center and the Erasmus Medical Center. In addition, surgeons from other centers were contacted individually. The conduct of this study was approved by the institutional medical ethics committee. SABR was delivered in an outpatient setting. In the VUmc, patients were treated as previously described, with individualized target volumes encompassing all motion on four-dimensional CT scans, with no active motion management 11. In the Erasmus MC, patients were treated with Cyberknife with real-time tumor tracking 12. All fractionation schemes had a biologically effective dose of >100 Gy 10 described to the planning target volume (PTV). In each case we retrospectively calculated the maximum dose delivered to the ipsilateral proximal bronchial tree. Post-treatment follow-up generally consisted of a contrast-enhanced CT-scan of the thorax and abdomen carried out at 2-3 months after treatment, 6-monthly for 2 years, and annually thereafter. In the event patients were not followed up at our centers, attending lung physicians and surgeons were contacted for all details related to the diagnosis of

5 Chapter 10 local recurrence, and any subsequent surgery. Local failure was defined as a suspected recurrence in, or adjacent to, the PTV. The diagnosis of local recurrence was based on CT and/or 18 FDG PET scans. All patients were referred for surgical salvage of the local recurrence. Complications following surgery were classified using the Dindo-Clavien classification 13. Follow-up was calculated using the reverse Kaplan-Meier method 14. Time-to-event outcomes were analyzed using the Kaplan Meier method. Results Twenty patients with a suspected local recurrence for which they underwent surgery were identified. Three patients were excluded from further analysis. One patient was excluded as details of the surgical procedure and the post-operative course were unavailable; However this patient died of unrelated causes, 39 months after undergoing surgery. Another patient excluded had a pre-operative diagnosis of mediastinal lymph node metastasis, and a third had previous large-field conventional thoracic radiotherapy in addition to SABR. Details of the remaining seventeen patients, comprising 21 resections, are summarized in table 1. Four patients who were treated for oligo-lung metastases of a colorectal carcinoma, each underwent two resections for local recurrences of separate lesions. Nine patients underwent resection for a local recurrence of early stage NSCLC, and eight patients for a local recurrence of a treated pulmonary metastasis. Fifteen of seventeen patients presenting with a local recurrence of an early stage NSCLC had an isolated local recurrence. In addition, one patient had a solitary adrenal gland metastasis, and the other had a histologically confirmed recurrence in a single 18 FDG-PET positive hilar node. All patients had peripheral tumors with a mean diameter of 19.6 mm (SD±10.3), and the median PTV was 16.5 mm3 (range mm3). The maximum dose in the ipsilateral proximal bronchial tree structures was below 30Gy in all patients and below 20Gy in all but one patient.

6 Table 1: Patient Characteristics Surgical salvage for local failures following SABR 153 Patients treated for primary NSCLC (N=9) N(%) / median (range) Patients treated for solitary metastasis (N = 8 / N = 12) N(%) / median (range) Age (years) 65 (54-71) 62 (44-74) Gender - M - F Tumor location - LUL - LLL - RUL - RML - RLL Fractionation scheme - 1x30Gy - 3x20Gy - 3x17Gy - 5x11Gy - 5x12Gy - 8x7,5Gy Diagnosis of LR - CT + PET + PA - CT + PET - CT only 6 (67%) 3 (33%) 4 (44% 3 (33%) (44%) 5 (56%) 4 (44%) - 7 (88%) 1 (13%) 3 (25%) 3 (25%) 3(25%) 1(8%) 2 (17%) 3 (25%) 4 (33%) 3 (25%) 1 (8%) - 1 (8%) - 7 (88%) 1 (13% Time to local recurrence 22 (9 34) 13 (6-48) Tumor stage - T1aN0M0 - T1bN0M0 - T2aN0M0 - T2bN0M0 Pathology before SABR - Adenocarcinoma - Squamous cell - NSCLC - No 4 (44%) 3 (33%) LUL: Left upper lobe. RML: Right middle lobe. LLL: left lower lobe. RUL: Right upper lobe. LR: local recurrence. CT: Computed tomography imaging. PET: Positron emission tomography imaging. PA: Pathology. All 17 patients who were initially considered to be medically operable and surgically resectable at the time of diagnosis, but were referred for SABR following discussions in a multidisciplinary tumor board and with patients themselves. Similarly, all patients who underwent salvage surgery were discussed in multidisciplinary tumor boards. The

7 Chapter 10 median Charlson co-morbidity index was 1 (range 0-7) 15. Lung function tests before SABR and surgery were available in 10 patients, including all patients who were treated for a local recurrence of a primary NSCLC. The mean predicted FEV1% of before SABR was 76% ± 26%, whereas it was 72% ±20% at the time of the diagnosis of a local recurrence (p=0.123). Median time to the diagnosis of local recurrence following SABR was 15.6 months (range 6-48 months). All patients had a growing lesion on consecutive CT-scans. In all but one patient, the clinical diagnosis of a local recurrence was based on positive 18 FDG-PETscans. However, the diagnosis of local recurrence was pathologically confirmed before surgery in only four patients. In another patient, a cytology specimen obtained by endobronchial brushings was suggestive for malignancy. Details of the surgical procedures are summarized in Table 2. A lobectomy was performed during 15 resections, three of which were performed by video-assisted thoracoscopic surgery (VATS). In one patient, a planned VATS-lobectomy was converted to an open pneumonectomy due to extensive peritumoral and pleural adhesions. One patient underwent a sleeve-lobectomy as a pre-operative endobronchial ultrasound showed hilar lymph node metastasis. Three patients underwent a wedge-resection, one of which was performed with VATS, because of the small tumor size and in another patient a segmental resection was performed. Due to the prior SABR, special attention was paid to intra-operative findings. During nine out of the 21 resections, no noteworthy findings were observed, while in seven other resections, limited intra-thoracic adhesions were observed. Extensive adhesions were observed during five procedures, which necessitated conversion from a VATS to an open procedure in three patients, which led to an open pneumonectomy in one patient with extensive peritumoral and pleural adhesions. As intra-operative extensive tumor growth into the visceral pleura and pericardial fat was found, it is unclear whether these adhesions were caused only by tumor progression, or were due to the SABR treatment delivered using the largest PTV in this series. The remaining patient had a conversion from a VATS to an open-procedure due to tumor location. In only two patients the bronchial stump was covered with an intercostal muscle flap. A complete resection with free resection margins was obtained in all but one patient, who underwent a pneumonectomy with evidence of tumor growth into the pericardial fat.

8 Table 2: Surgical outcome Type of resectionl - Lobectomy - VATS - Lobectomy - Sleeve-lobectomy - Pneumonectomy - Segment resection - Wedge resection - VATS - wedge resection Intra-operative findings - No adhesions - Limited adhesions - Extensive adhesions ptnm (NSCLC patients only) - T1N0 - T2N0 - T1N2 - T2N2 - T3N0 - T3N2 - T4N0 Radicality of resection - R0 - R2 Surgical complications - No - Grade 2 - Grade 3a Surgical salvage for local failures following SABR 155 N(%) or Median (range) 15 (71%) 3 (14%) 1 (5%) 1 (5%) 1 (5%) 3 (14%) 1 (5%) 9 (43%) 7 (33%) 5 (24%) 20 (95%) 1 (5%) 17 (81%) 2 (10%) 2 (10%) Length of hospital stay 7 (4-15) Four patients experienced complications grade 2 or higher following surgery, which in two cases was due to an infection treated with oral antibiotics (grade II complication). Two other patients, one of whom underwent a sleeve-lobectomy, developed persistent airway leakage, which was treated with a new thoracic tube (grade IIIa complication). There was no bronchopleural fistula present in these patients. The median length of hospital stay was 7 days (range 4-15 days) and 30-day mortality was 0%. In all patients, viable tumor cells were identified on pathological examination. Necrosis was described by the pathologists in eleven cases and fibrosis in six. Five patients had disease upstaging during surgery; one patient had a T3 tumor, three patients had mediastinal lymph node metastases, and one patient had direct extension in the visceral pleura and pericardial fatty tissue. All patients who were upstaged received adjuvant therapy consisting of chemotherapy (n=4) and radiotherapy (n=1).

9 Chapter 10 Median follow-up after surgery was 40.6 months. Five patients developed further diseaseprogression after surgery. Of these, three patients, all treated for oligo-metastases, developed further metastatic disease. Two patients treated for a local recurrence of a NSCLC developed further disease progression, one of whom had regional failure and subsequent distant failure, the other patient developed distant metastasis. Median overall survival after surgery was 38 months. Estimated actuarial survival at 1-year was 100%, and was 80% at 2-years post-surgery. Five patients died during follow-up, three patients due to unrelated causes, two patients died due to disease progression. Figure 1: Example of a patient with a local recurrence following SABR for NSCLC. A: CT-scan at the time of diagnosis of the primary tumor. B: CT-scan one year post SABR. C: CT-scan at the time of local recurrence. D: histological specimen of this patient showing poorly differentiated tumor cells (100x enlarged)

10 Surgical salvage for local failures following SABR 157 Discussion In this report, we present the largest series to date of patients who underwent surgical salvage for a resectable local recurrence following SABR treatment for a pulmonary malignancy. Our findings demonstrate that local failures following SABR can be successfully and safely salvaged in selected patients, as 95% of the resections were R0 and only two resections were complicated by > grade 2 toxicity (10%). The median length of hospital stay was within the normal range and 30-day mortality was 0% 16. Furthermore, median overall survival following surgery was 38 months. Previous reports on surgery for local recurrence after SABR have mainly originated from Japan, where pioneering work on SABR has been performed Even though both Japanese and Western studies report using SABR doses to a BED of >100Gy, actual doses delivered differ as European guidelines recommend that this dose encompasses the PTV [17], while the Japanese practice had been to prescribe this dose the tumor isocenter 18. While delivering higher tumor doses to our patients, there is also a risk of higher doses to normal organs in the proximity, with potentially more problems with wound-healing after surgical procedures. This problem was not evident in our patients, which can be attributed to the fact that all our patients were treated for peripheral lung tumors using conformal treatment plans, resulting in low dose received by the proximal bronchial tree. During five resections (24%), extensive adhesions were seen causing conversion from a VATS procedure to an open procedure in three patients. The conversion rate in four of our eight thoracoscopic procedures is higher than generally reported 19,20. However, all but one resection could be safely and completely performed without the need for more extensive resection. Although only five patients had pathological confirmation of local recurrence before they underwent surgery, it should be pointed out that recent ESMO guidelines have recommend that all such cases should ideally have a pathological diagnosis before proceeding to surgery 1, especially given the difficulties in distinguishing fibrosis from recurrences 21. Our findings support the recommendation of periodic thoracic CT-scans after SABR for pulmonary malignancies, to detect local recurrence in a timely fashion 1. Our experience suggests surgical salvage can be safely performed in selected patients. However, as the number of patients in our report is still relatively limited and restricted to specialist centers, our findings need to be confirmed in additional series.

11 Chapter 11 References 1. Vansteenkiste J, Crinò L, Dooms C, et al. 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol 2014;25: Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e278S 313S. 3. Louie AV, Senthi S, Palma DA. Surgery versus SABR for NSCLC. Lancet Oncol 2013;14:e Louie AV, Palma DA, Dahele M, et al. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: Controversies, insights, and changing horizons. Radiother Oncol 2015;114: Zhang B, Zhu F, Ma X, et al. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: A systematic review and meta-analysis. Radiother Oncol 2014;112: Lagerwaard FJ, Verstegen NE, Haasbeek CJA, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2012;83: Peguret N, Dahele M, Lagerwaard F, et al. A brief report of 10-year trends in the use of stereotactic lung radiotherapy at a dutch academic medical center. J Thorac Oncol 2014;9: Chen F, Matsuo Y, Yoshizawa A, et al. Salvage lung resection for non-small cell lung cancer after stereotactic body radiotherapy in initially operable patients. J Thorac Oncol 2010;5: Neri S, Takahashi Y, Terashi T, et al. Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers. J Thorac Oncol 2010;5: Allibhai Z, Cho BCJ, Taremi M, et al. Surgical salvage following stereotactic body radiotherapy for early-stage NSCLC. Eur Respir J 2012;39: Lagerwaard FJ, Haasbeek CJA, Smit EF, et al. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;70: Nuyttens JJ, van de Pol M. The CyberKnife radiosurgery system for lung cancer. Expert Rev Med Devices 2012;9: Dindo D, Demartines N, Clavien PA. Classification of Surgical Complications. Ann Surg 2004;240: Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17: Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40: Whitson BA, Groth SS, Duval SJ, et al. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg 2008;86: Vansteenkiste J, De Ruysscher D, Eberhardt WEE, et al. Early and locally advanced non-smallcell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and

12 Conclusions and future directions 159 follow-up. Ann Oncol 2013;24 Suppl 6:vi Suzuki O, Mitsuyoshi T, Miyazaki M, et al. Dose-volume-response analysis in stereotactic radiotherapy for early lung cancer. Radiother Oncol 2014;112: Lee PC, Nasar A, Port JL, et al. Long-term survival after lobectomy for non-small cell lung cancer by video-assisted thoracic surgery versus thoracotomy. Ann Thorac Surg 2013;96:951 60; 20. Whitson BA, Andrade RS, Boettcher A, et al. Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer. Ann Thorac Surg 2007;83: Huang K, Senthi S, Palma DA, et al. High-risk CT features for detection of local recurrence after stereotactic ablative radiotherapy for lung cancer. Radiother Oncol 2013;109:51 7.

Response Evaluation after Stereotactic Ablative Radiotherapy for Lung Cancer

Response Evaluation after Stereotactic Ablative Radiotherapy for Lung Cancer Original Article PROGRESS in MEDICAL PHYSICS Vol. 26, No. 4, December, 2015 http://dx.doi.org/10.14316/pmp.2015.26.4.229 Response Evaluation after Stereotactic Ablative Radiotherapy for Lung Cancer Ji

More information

Stereotactic body radiation therapy versus surgery for patients with stage I non-small cell lung cancer

Stereotactic body radiation therapy versus surgery for patients with stage I non-small cell lung cancer Review Article Page 1 of 9 Stereotactic body radiation therapy versus surgery for patients with stage I non-small cell lung cancer Tomoki Kimura Department of Radiation Oncology, Hiroshima University Hospital,

More information

Therapy of Non-Operable early stage NSCLC

Therapy of Non-Operable early stage NSCLC SBRT Stage I NSCLC Therapy of Non-Operable early stage NSCLC Dr. Adnan Al-Hebshi MD, FRCR(UK), FRCP(C), ABR King Faisal Specialist Hospital & Research Centre This is our territory Early Stages NSCLC Surgical

More information

Changes in TNM-classification 7 th edition T T1 2 cm T1a

Changes in TNM-classification 7 th edition T T1 2 cm T1a Introduction 1 Chapter 1 Introduction 9 Currently, cancer is the second leading cause of death in Europe 1. Globally, lung cancer is by far the most common cause of cancer-related deaths, and is by itself

More information

Stereotactic ablative radiotherapy in early NSCLC and metastases

Stereotactic ablative radiotherapy in early NSCLC and metastases Stereotactic ablative radiotherapy in early NSCLC and metastases Scheduled: 0810-0830 hrs, 10 March 2012 Professor Suresh Senan Department of Radiation Oncology SABR in stage I NSCLC A major treatment

More information

and Strength of Recommendations

and Strength of Recommendations ASTRO with ASCO Qualifying Statements in Bold Italics s patients with T1-2, N0 non-small cell lung cancer who are medically operable? 1A: Patients with stage I NSCLC should be evaluated by a thoracic surgeon,

More information

- In potentially operable patients -

- In potentially operable patients - Lung Stereotactic Ablative Radiotherapy (SABR) - In potentially operable patients - Frank Lagerwaard VUMC Amsterdam Stereotactic Ablative Radiotherapy (SABR) 2003-2008 4DCT-based target definition Non-gated

More information

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL

LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert

More information

Cheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda

Cheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

SABR. Outline. Stereotactic Radiosurgery. Stereotactic Radiosurgery. Stereotactic Ablative Radiotherapy

SABR. Outline. Stereotactic Radiosurgery. Stereotactic Radiosurgery. Stereotactic Ablative Radiotherapy CAGPO Conference October 25, 2014 Outline Stereotactic Radiation for Lung Cancer and Oligometastatic Disease What Every GPO should know Dr. David Palma, MD, MSc, PhD Radiation Oncologist, London Health

More information

Utility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer

Utility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department

More information

S. Mokhles N.E. Verstegen A.P.W.M. Maat Ö. Birim A.J. Bogers. M.M. Mokhles F.J. Lagerwaard S. Senan J.J. Takkenberg. Lung Cancer 2015; 87(3):

S. Mokhles N.E. Verstegen A.P.W.M. Maat Ö. Birim A.J. Bogers. M.M. Mokhles F.J. Lagerwaard S. Senan J.J. Takkenberg. Lung Cancer 2015; 87(3): S. Mokhles N.E. Verstegen A.P.W.M. Maat Ö. Birim A.J. Bogers M.M. Mokhles F.J. Lagerwaard S. Senan J.J. Takkenberg Lung Cancer 2015; 87(3): 283-289 7 Comparison of clinical outcome of stage I nonsmall

More information

THORACIC MALIGNANCIES

THORACIC MALIGNANCIES THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,

More information

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new

More information

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.

Case Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma. Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest

More information

Larry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017

Larry Tan, MD Thoracic Surgery, HSC. Community Cancer Care Educational Conference October 27, 2017 Larry Tan, MD Thoracic Surgery, HSC Community Cancer Care Educational Conference October 27, 2017 To describe patient referral & triage for the patient with suspected lung cancer To describe the initial

More information

Thoracic Recurrences. Soft tissue recurrence

Thoracic Recurrences. Soft tissue recurrence Stereotactic body radiotherapy for thoracic and soft malignancies Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of

More information

Although video-assisted thoracoscopic surgery (VATS)

Although video-assisted thoracoscopic surgery (VATS) Original Article Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non Small-Cell Lung Cancer Importance of Salvage Surgery Masatsugu Hamaji, MD,*

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated

More information

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave

FDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.

More information

Local control rates exceeding 90% have been reported using

Local control rates exceeding 90% have been reported using ORIGINAL ARTICLE Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer Eva M. Bongers, MD, Cornelis J. A. Haasbeek, MD, PhD, Frank

More information

VATS after induction therapy: Effective and Beneficial Tips on Strategy

VATS after induction therapy: Effective and Beneficial Tips on Strategy VATS after induction therapy: Effective and Beneficial Tips on Strategy AATS Focus on Thoracic Surgery Mastering Surgical Innovation Las Vegas Nevada Oct. 27-28 2017 Scott J. Swanson, M.D. Professor of

More information

SURGICAL TECHNIQUE. Radical treatment for left upper-lobe cancer via complete VATS. Jun Liu, Fei Cui, Shu-Ben Li. Introduction

SURGICAL TECHNIQUE. Radical treatment for left upper-lobe cancer via complete VATS. Jun Liu, Fei Cui, Shu-Ben Li. Introduction SURGICAL TECHNIQUE Radical treatment for left upper-lobe cancer via complete VATS Jun Liu, Fei Cui, Shu-Ben Li The First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China ABSTRACT KEYWORDS

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY?

STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY? STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY? MICHAEL LANUTI, MD American Association of Thoracic Surgeons Minneapolis, MN 2013 STAGE I INOPERABLE NSCLC RADIOFREQUENCY

More information

Parenchyma-sparing lung resections are a potential therapeutic

Parenchyma-sparing lung resections are a potential therapeutic Lung Segmentectomy for Patients with Peripheral T1 Lesions Bryan A. Whitson, MD, Rafael S. Andrade, MD, and Michael A. Maddaus, MD Parenchyma-sparing lung resections are a potential therapeutic option

More information

Complex Thoracoscopic Resections for Locally Advanced Lung Cancer

Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,

More information

Adam J. Hansen, MD UHC Thoracic Surgery

Adam J. Hansen, MD UHC Thoracic Surgery Adam J. Hansen, MD UHC Thoracic Surgery Sometimes seen on Chest X-ray (CXR) Common incidental findings on computed tomography (CT) chest and abdomen done for other reasons Most lung cancers discovered

More information

Mediastinal Staging. Samer Kanaan, M.D.

Mediastinal Staging. Samer Kanaan, M.D. Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor

More information

Surgical management of lung cancer

Surgical management of lung cancer Surgical management of lung cancer Nick Roubos FRACS Cardiothoracic Surgeon Box Hill Hospital, Epworth Eastern Thoracic Oncology Non Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Mesothelioma Pulmonary

More information

Clinical Study Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Lung Tumors in the State of Oligo-Recurrence

Clinical Study Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Lung Tumors in the State of Oligo-Recurrence Pulmonary Medicine Volume 2012, Article ID 369820, 5 pages doi:10.1155/2012/369820 Clinical Study Clinical Outcomes of Stereotactic Body Radiotherapy for Patients with Lung Tumors in the State of Oligo-Recurrence

More information

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer

Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD

Lung Cancer. Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Lung Cancer Current Therapy JEREMIAH MARTIN MBBCh FRCSI MSCRD Objectives Describe risk factors, early detection & work-up of lung cancer. Define the role of modern treatment options, minimally invasive

More information

Treatment of oligometastatic NSCLC

Treatment of oligometastatic NSCLC Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

Lung Cancer Clinical Guidelines: Surgery

Lung Cancer Clinical Guidelines: Surgery Lung Cancer Clinical Guidelines: Surgery 1 Scope of guidelines All Trusts within Manchester Cancer are expected to follow this guideline. This guideline is relevant to: Adults (18 years and older) with

More information

ACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD

ACOSOG Thoracic Committee. Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy Govindan, M.D. Carolyn Reed, MD

More information

Flattening Filter Free beam

Flattening Filter Free beam Dose rate effect in external radiotherapy: biology and clinic Marta Scorsetti, M.D. Radiotherapy and Radiosurgery Dep., Istituto Clinico Humanitas, Milan, Italy Brescia October 8th/9th, 2015 Flattening

More information

THORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS

THORACIK RICK. Lungs. Outline and objectives Richard A. Malthaner MD MSc FRCSC FACS THORACIK RICK Outline and objectives Lungs Management of a solitary lung nodule Mediastinum Management of a mediastinal mass Pleura Management of a pleural fluid & pneumothorax Esophagus & Stomach Management

More information

Protocol of Radiotherapy for Small Cell Lung Cancer

Protocol of Radiotherapy for Small Cell Lung Cancer 107 年 12 月修訂 Protocol of Radiotherapy for Small Cell Lung Cancer Indication of radiotherapy Limited stage: AJCC (8th edition) stage I-III (T any, N any, M0) that can be safely treated with definitive RT

More information

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo

More information

Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard

Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical

More information

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No

More information

Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer

Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,

More information

The Itracacies of Staging Patients with Suspected Lung Cancer

The Itracacies of Staging Patients with Suspected Lung Cancer The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung

More information

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,

More information

ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD

ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy

More information

Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice?

Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? E.Molfese, P.Matteucci, A.Iurato, L.E.Trodella, A.Sicilia, B.Floreno, S.Ramella, L.Trodella Radioterapia Oncologica, Università Campus

More information

EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI

EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced

More information

Case presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium

Case presentation. Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Case presentation Paul De Leyn, MD, PhD Thoracic Surgery University Hospitals Leuven Belgium Perspectives in Lung Cancer Brussels 6-7 march 2009 LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery

More information

Stereotactic ablative radiotherapy (SABR) for early-stage lung cancer. Professor Suresh Senan VU University Medical Center Amsterdam, The Netherlands

Stereotactic ablative radiotherapy (SABR) for early-stage lung cancer. Professor Suresh Senan VU University Medical Center Amsterdam, The Netherlands Stereotactic ablative radiotherapy (SABR) for early-stage lung cancer Professor Suresh Senan VU University Medical Center Amsterdam, The Netherlands Disclosures Research support: Varian Medical Systems

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

Chapter 6. H. Tekatli* M. Duijm* E. Oomen-de Hoop W. Verbakel W. Schillemans B. Slotman J. Nuyttens S. Senan

Chapter 6. H. Tekatli* M. Duijm* E. Oomen-de Hoop W. Verbakel W. Schillemans B. Slotman J. Nuyttens S. Senan Normal tissue complication probability modeling of pulmonary toxicity after stereotactic and hypofractionated radiation therapy for central lung tumors H. Tekatli* M. Duijm* E. Oomen-de Hoop W. Verbakel

More information

Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery

Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery Stereotactic Body Radiation Therapy and Radiofrequency Ablation 2014 Masters of Minimally Invasive Surgery Matthew Hartwig, M.D. Duke Cancer Institute Case Presentation I: Patient ER 74 y/o male with A1A

More information

Inflammatory Pseudotumor Suspected of Lung Cancer Treated by Thoracoscopic Resection

Inflammatory Pseudotumor Suspected of Lung Cancer Treated by Thoracoscopic Resection Ann Thorac Cardiovasc Surg 2011; 17: 48 52 Case Report Inflammatory Pseudotumor Suspected of Lung Cancer Treated by Thoracoscopic Resection Shinji Hirai, MD, 1 Tatsuya Katayama, MD, 1 Naru Chatani, MD,

More information

Radiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer

Radiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer Radiofrequency ablation combined with conventional radiotherapy: a treatment option for patients with medically inoperable lung cancer Poster No.: C-0654 Congress: ECR 2011 Type: Scientific Paper Authors:

More information

Charles Mulligan, MD, FACS, FCCP 26 March 2015

Charles Mulligan, MD, FACS, FCCP 26 March 2015 Charles Mulligan, MD, FACS, FCCP 26 March 2015 Review lung cancer statistics Review the risk factors Discuss presentation and staging Discuss treatment options and outcomes Discuss the status of screening

More information

Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors

Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors Chapter 6 Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors Gwendolyn H.M.J. Griffioen 1, Daniel Toguri 2, Max Dahele 1, Andrew

More information

20. Background. Oligometastases. Oligometastases: bone (including spine) and lymph nodes

20. Background. Oligometastases. Oligometastases: bone (including spine) and lymph nodes 125 20. Oligometastases Background The oligometastatic state can be defined as 1 3 isolated metastatic sites, typically occurring more than six months after successful treatment of primary disease. 1 In

More information

Sagar Damle, MD University of Colorado Denver May 23, 2011

Sagar Damle, MD University of Colorado Denver May 23, 2011 Sagar Damle, MD University of Colorado Denver May 23, 2011 We have debated many times. Here are the topics, and a recap of the last few Pre-operative nutrition Babu pro; Damle con Utility of ECMO Babu

More information

Surgery for early stage NSCLC

Surgery for early stage NSCLC 1-3 March 2017, Manchester, UK Surgery for early stage NSCLC Dominique H. Grunenwald, MD, PhD Professor Emeritus in Thoracic and Cardiovascular surgery Pierre & Marie Curie University. Paris. France what

More information

Uniportal video-assisted thoracic surgery for complicated pulmonary resections

Uniportal video-assisted thoracic surgery for complicated pulmonary resections Review Article on Thoracic Surgery Uniportal video-assisted thoracic surgery for complicated pulmonary resections Ding-Pei Han, Jie Xiang, Run-Sen Jin, Yan-Xia Hu, He-Cheng Li Jiaotong University School

More information

Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame

Outline. WBRT field. Brain Metastases. Whole Brain RT Prophylactic WBRT Stereotactic radiosurgery (SRS) 1 fraction Stereotactic frame Radiation Therapy for Advanced NSC Lung Ca Alexander Gottschalk, M.D., Ph.D. Associate Professor Director of CyberKnife Radiosurgery Department of Radiation Oncology University of California San Francisco

More information

Routine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF)

Routine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF) Routine reinforcement of bronchial stump after lobectomy or pneumonectomy with pedicled pericardial flap (PPF) Abstract The results of 25 cases underwent a pedicled pericardial flap coverage for the bronchial

More information

Educational Objectives. Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach.

Educational Objectives. Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach. Managing Lung Cancer From the Solitary Pulmonary Nodule to Complex Cases: A Multidisciplinary Approach Robert A. Meguid, MD, MPH, FACS Assistant Professor of Cardiothoracic Surgery Surgical Director, Surgical

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566

More information

Reasons for conversion during VATS lobectomy: what happens with increased experience

Reasons for conversion during VATS lobectomy: what happens with increased experience Review Article on Thoracic Surgery Page 1 of 5 Reasons for conversion during VATS lobectomy: what happens with increased experience Dario Amore, Davide Di Natale, Roberto Scaramuzzi, Carlo Curcio Division

More information

Chirurgie beim oligo-metastatischen NSCLC

Chirurgie beim oligo-metastatischen NSCLC 24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital

More information

Bronchogenic Carcinoma

Bronchogenic Carcinoma A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most

More information

PLACE LABEL HERE. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form. RTOG Study No.

PLACE LABEL HERE. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form. RTOG Study No. Radiation Therapy Oncology Group Phase II - SBRT - Medically Inoperable I /II NSCLC Follow-up Form RTOG Study No. 0813 Case # Name RTOG Patient ID INSTRUCTIONS: Submit this form at the appropriate followup

More information

ROBOT SURGEY AND MINIMALLY INVASIVE TREATMENT FOR LUNG CANCER

ROBOT SURGEY AND MINIMALLY INVASIVE TREATMENT FOR LUNG CANCER ROBOT SURGEY AND MINIMALLY INVASIVE TREATMENT FOR LUNG CANCER Giulia Veronesi European Institute of Oncology Milan Lucerne, Samo 24 th - 25 th January, 2014 DIAGNOSTIC REVOLUTION FOR LUNG CANCER - Imaging

More information

Tecniche Radioterapiche U. Ricardi

Tecniche Radioterapiche U. Ricardi Tecniche Radioterapiche U. Ricardi UNIVERSITA DEGLI STUDI DI TORINO Should we always rely on stage? T4N0M0 Stage IIIB T2N3M0 Early stage NSCLC The treatment of choice for early-stage NSCLC is anatomic

More information

Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion

Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion Pieter Postmus The Clatterbridge Cancer Centre Liverpool Heart and Chest Hospital Liverpool, United Kingdom 1 2

More information

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED

More information

Thoracoscopic left upper lobectomy with systematic lymph nodes dissection under left pulmonary artery clamping

Thoracoscopic left upper lobectomy with systematic lymph nodes dissection under left pulmonary artery clamping GCTAB Column Thoracoscopic left upper lobectomy with systematic lymph nodes dissection under left pulmonary artery clamping Yi-Nan Dong, Nan Sun, Yi Ren, Liang Zhang, Ji-Jia Li, Yong-Yu Liu Department

More information

Lung SBRT in a patient with poor pulmonary function

Lung SBRT in a patient with poor pulmonary function Lung SBRT in a patient with poor pulmonary function CASE STUDY Delivered using Versa HD with High Dose Rate mode and Symmetry 4D image guidance Institution: Department of Oncology, Odense University Hospital

More information

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018 30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective

More information

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji

More information

DIAGNÓSTICO Y TERAPIAS LOCALES. Rosario García Campelo Servicio de Oncología Médica Complejo Hospitalario Universitario A Coruña

DIAGNÓSTICO Y TERAPIAS LOCALES. Rosario García Campelo Servicio de Oncología Médica Complejo Hospitalario Universitario A Coruña DIAGNÓSTICO Y TERAPIAS LOCALES Rosario García Campelo Servicio de Oncología Médica Complejo Hospitalario Universitario A Coruña SIDNEY 2013 THE CHALLENGE THE THREE SISTERS: IMAGING, PATHOLOGY AND LOCAL

More information

Reirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze

Reirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze Reirradiazione La radioterapia stereotassica ablativa: torace Pierluigi Bonomo Firenze Background Stage III NSCLC isolated locoregional recurrence in 25% of pts mostly unresectable; low RR with 2 nd line

More information

Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany

Lung cancer Surgery. 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY March, 2017 Berlin, Germany 17 TH ESO-ESMO MASTERCLASS IN CLINICAL ONCOLOGY 24-29 March, 2017 Berlin, Germany Lung cancer Surgery Sven Hillinger MD, Thoracic Surgery, University Hospital Zurich Case 1 59 y, female, 40 py, incidental

More information

Non-small cell lung cancer (NSCLC) is the leading cause

Non-small cell lung cancer (NSCLC) is the leading cause ORIGINAL ARTICLE Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J. Slotman, MD, PhD, and

More information

Lung Cancer Update. Disclosures. None

Lung Cancer Update. Disclosures. None Lung Cancer Update Ronald J Servi DO FCCP Adjunct Assistant Professor Department of Pulmonary Medicine University of Texas MD Anderson Cancer Center Banner MD Anderson Cancer Center Gilbert, Arizona Disclosures

More information

RF Ablation: indication, technique and imaging follow-up

RF Ablation: indication, technique and imaging follow-up RF Ablation: indication, technique and imaging follow-up Trongtum Tongdee, M.D. Radiology Department, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand Objective Basic knowledge

More information

Radiological changes following stereotactic radiotherapy for stage I lung cancer. M. Dahele, D. Palma, F. Lagerwaard, B. Slotman, S.

Radiological changes following stereotactic radiotherapy for stage I lung cancer. M. Dahele, D. Palma, F. Lagerwaard, B. Slotman, S. Chapter 9 Radiological changes following stereotactic radiotherapy for stage I lung cancer M. Dahele, D. Palma, F. Lagerwaard, B. Slotman, S. Senan Department of Radiation Oncology, VU University Medical

More information

Thoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014

Thoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery

More information

The tumor, node, metastasis (TNM) staging system of lung

The tumor, node, metastasis (TNM) staging system of lung ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,

More information

Treatment of oligometastases: Lung

Treatment of oligometastases: Lung Treatment of oligometastases: Lung Themadag Catharina ZH 30 March 2017 Max Dahele Radiation Oncologist Vumc, Amsterdam m.dahele@vumc.nl Do you all treat lung oligometastases? What is your definition of

More information

OBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules.

OBJECTIVES. Solitary Solid Spiculated Nodule. What would you do next? Case Based Discussion: State of the Art Management of Lung Nodules. Organ Imaging : September 25 2015 OBJECTIVES Case Based Discussion: State of the Art Management of Lung Nodules Dr. Elsie T. Nguyen Dr. Kazuhiro Yasufuku 1. To review guidelines for follow up and management

More information

Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib

Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department

More information

Carcinoma of the Lung

Carcinoma of the Lung THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and

More information

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department

More information

Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer

Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department

More information

Lara Kujtan, MD; Abdulraheem Qasem, MD

Lara Kujtan, MD; Abdulraheem Qasem, MD The Treatment of Lung Cancer Between 2013-2014 at Truman Medical Center: A Retrospective Review in Fulfillment of the Requirements of Standard 4.6 (Monitoring Compliance with Evidence- Based Guidelines)

More information

Indications for sublobar resection for localized NSCLC

Indications for sublobar resection for localized NSCLC Indications for sublobar resection for localized NSCLC David H Harpole Jr, MD Professor of Surgery Associate Professor in Pathology Vice Chief, Division of Surgical Services Duke University School of Medicine

More information

NHS England. Evidence review: Stereotactic Ablative Radiotherapy for Non Small Cell Lung Cancer

NHS England. Evidence review: Stereotactic Ablative Radiotherapy for Non Small Cell Lung Cancer NHS England Evidence review: Stereotactic Ablative Radiotherapy for Non Small Cell Lung Cancer NHS England Evidence review: Stereotactic ablative radiotherapy for non small cell lung cancer First published:

More information

came from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary

came from a carcinoma and in 12 from a sarcoma. Ninety lesions were intrapulmonary and the as the chest wall and pleura. Details of the primary Thorax 1982;37:366-370 Thoracic metastases MARY P SHEPHERD From the Thoracic Surgical Unit, Harefield Hospital, Harefield ABSTRACI One hundred and four patients are reviewed who were found to have thoracic

More information

Innovations in Lung Cancer Diagnosis and Surgical Treatment

Innovations in Lung Cancer Diagnosis and Surgical Treatment Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information